ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clini ...

Kester Capital-backed Evestia Clinical merges with US-based Atlantic Research Group (ARG) to create a leading independent global specialist CRO in fast-growing marketsThe merger delivers on Evestia ...

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by ...

STOCKHOLM, SE / ACCESS Newswire / July 15, 2025 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

Dr. Vincent Ma discussed the most recent and notable treatment updates for patients with high-risk and advanced melanoma.

Researchers at the La Jolla-based Salk Institute for Biological Studies say they recently identified a brain circuit that ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...